John Montalbano, a Director, acquired 243,900 Common Shares on a direct ownership basis at a price of $1.750 through a prospectus or prospectus exempt offering on April 20th, 2022. The insider also acquired 243,900 Warrants with an exercise price of $3.000. This represents a $426,825 investment into the company's shares and an account share holdings change of 27.9%.
In addition, Bruce Gordon Cousins, a Senior Officer, acquired 100,000 Common Shares and 100,000 Warrants on a direct ownership basis. This represents a $175,000 investment into the company's shares and an account share holdings change of greater than 100%.
Eupraxia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company with a drug delivery technology platform. The Company's lead product candidate EP-104IAR, is developed for the treatment long-lasting pain relief for knee osteoarthritis (OA). In addition to EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. The Company's pipeline candidates include a range of drugs for indications such as post-surgical anesthetic (EP-105) and post-surgical site infections (EP-201). The Company is also engaged in the development of candidates to its pipeline including an internally developed oncology product. The Company is also engaged in developing a formulation of EP-104IAR for use in canine and equine OA.
No Comments